Club Drugs (cont.)
MDMA (ecstasy) and brain changes. This image shows the brain scans of a person who has never used MDMA (top) compared with scans of a person who used MDMA for an extended period of time up until three weeks before the images were taken. Specifically, the scans show the brain's ability to transport a neurotransmitter called serotonin from the synapse back into the releasing neuron (the brighter colors). Serotonin is fundamental to the brain's ability to handle information and express emotion. Such findings are leading researchers to conclude that an ecstasy user may be at risk of long-term, perhaps permanent, problems with learning and memory. Image courtesy of the National Institute of Drug Abuse (NIDA). Click to view larger image.
Long-term effects of drug abuse. This brain scan shows that once you become addicted to a drug like cocaine, your brain is affected (and clearly changed) for a long time. The yellow shows a lot of brain activity in a normal person. Measured 10 days after using cocaine, a cocaine addict's brain shows much less normal activity. For this same person, even after 100 days without using cocaine, the brain was still not back to a normal level of functioning. Scientists are concerned that areas in the brain may never fully recover from drug abuse and addiction. Image courtesy of the National Institute of Drug Abuse (NIDA).Click to view larger image.
Long-term effects of ecstasy. This image shows sections taken from the neocortex (part of the brain) of monkeys that were given Ecstasy twice a day for four days (control monkeys were given saline). The section on the left, taken from the brain of a control monkey who was not given Ecstasy, shows the presence of a high level of serotonin. The middle section shows a section from a monkey two weeks after receiving Ecstasy. Most of the serotonin is gone. The section on the right shows a section from a monkey seven years after receiving Ecstasy. Although there has been some recovery of serotonin, the brain has still not returned to normal. Ecstasy interacts with specific targets in the brain. After repeated or long-term use, the neurons in the brain may not communicate with each other and might affect a user's mood, behavior, and memory. Image courtesy of the National Institute of Drug Abuse (NIDA).Click to view larger image.
Medically reviewed by Marina Katz, MD; American Board of Psychiatry & Neurology
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Treatment Revision. Washington, D.C.: American Psychiatric Association, 2000.
American Psychiatric Association. Practice Guideline and Resources for Treatment of Patients with Substance Use Disorders, Second Edition. Arlington, Virginia: American Psychiatric Association, 2006.
Anglin, D., K.L. Spears, and H.R. Hutson. "Flunitrazepam and its involvement in date or acquaintance rape." Acad Emerg Med.
4.4 Apr. 1997: 323-326.
Arria, A.M., G.S. Yacoubian, E. Fost, and E.D. Wish. "The pediatric forum: ecstasy use among club rave attendees." Arch Pediatr Adolesc Med.
156.3 Mar. 2002: 295-296.
Bialer, P.A. "Designer drugs in the general hospital." Psychiatr Clin North Am.
25.1 Mar. 2002: 231-243.
Brodie, J.D., B.G. Case, E. Figueroa, et al. "Randomized, double-blind, placebo-controlled trial of vigabatrin for the treatment of cocaine dependence in Mexican parolees."
American Journal of Psychiatry 166 (2009): 1269-1277.
Chermack, S.T., R.L. Murray, M.A. Walton, B.A. Booth, J. Wryobeck, and F.C. Blow. "Partner aggression among men and women in substance use disorder treatment: correlates of psychological and physical aggression and injury."
Drug and Alcohol Dependence 98 (1-2) Nov. 2008: 35-44.
Compton, W.M., Y.F. Thomas, F.S. Stinson, and B.F. Grant. "Prevalence, correlates, disability and comorbidity of DSM-IV drug abuse and dependence in the United States."
Archives of General Psychiatry 64.5 (2007): 566-576.
Craig, K., H.F. Gomez, J.L. McManus, and T.C. Bania. "Severe gamma-hydroxybutyrate withdrawal: a case report and literature review." J Emerg Med.
18.1 Jan 2000: 65-70.
Ellenhorn, M.J., D.G. Barceloux, eds. "Amphetamines and designer drugs." In: Ellenhorn's Medical Toxicology. 2nd ed. Baltimore, Md: Lippincott Williams & Wilkins, 1997: 340-348.
Etheridge, R.M., J.C. Smith, J.L. Rounds-Bryant, and R.L. Hubbard. "Drug abuse treatment and comprehensive services for adolescents."
Journal of Adolescent Research 16 (2001): 563-589.
Glennon, R.A., R. Young, M. Dukat, et al. "N-Methyl-1-(4-methoxyphenyl)-2-aminopropane (PMMA) and N-Methyl-1-(3,4-methylenedioxyphenyl)-2-aminopropane (MDMA) Produce Nonidentical Discriminative Stimuli in Rats."
Pharmacology Biochemistry and Behavior 86.3 Mar. 2007: 477-484.
Goldman, L.S., M. Genel, R.J. Bezman, and P.J. Slanetz. "Diagnosis and treatment of attention-deficit/hyperactivity disorder in children and adolescents. Council on Scientific Affairs, American Medical Association." JAMA.
279.14 Apr. 8, 1998: 1100-1107.
Hearing Before the Senate Caucus on International Narcotics Control. Looking the Other Way: Rave Promoters and Club Drugs. 107th Cong (Dec 2001) (testimony of G.R. Hanson, National Institute on Drug Abuse).
Iwata, K., G.B. O'Keefe, and A. Karanas. "Neurologic problems associated with chronic nitrous oxide abuse in a non-healthcare worker." Am J Med Sci.
322.3 Sept. 2001: 173-174.
Johnston, L.D., P.M. O'Malley, J.G. Bachman, and J.E. Schulenberg. Monitoring the Future: National Survey Results on Drug Use, 1975-2008, Volume II. Bethesda, Md.: National Institute on Drug Abuse, U.S. Dept. of Health and Human Services, National Institutes of Health, 2009.
Klein-Schwartz, W. "Abuse and toxicity of methylphenidate." Curr Opin Pediatr.
14.2 Apr. 2002: 219-23.
Koesters, S.C., P.D. Rogers, and C.R. Rajasingham. "MDMA ('ecstasy') and other 'club drugs'. The new epidemic." Pediatr Clin North Am.
49.2 Apr. 2002: 415-433.
Llana, M.E., and M.L. Crismon. "Methylphenidate: increased abuse or
appropriate use?" J Am Pharm Assoc (Wash).
39.4 July-Aug. 1999: 526-530.
Marx, J.A., ed. Rosen's Emergency Medicine: Concepts and Clinical Practice. 5th ed. St. Louis, Mo: Mosby, 2002: 2119-2215.
McCann, U.D., V. Eligulashvili, and G.A. Ricaurte. "(+/-)3,4-Methylenedioxymethamphetamine ('Ecstasy')-induced serotonin neurotoxicity: clinical studies." Neuropsychobiology.
42.1 (2000): 11-16.
McCann, U.D., Z. Szabo, U. Scheffel, et al. "Positron emission tomographic evidence of toxic effect of MDMA ("Ecstasy") on brain serotonin neurons in human beings." Lancet.
352.9138 Oct. 31, 1998: 1433-1437.
Smith, K.M., L.L. Larive, and F. Romanelli. "Club drugs: methylenedioxymethamphetamine, flunitrazepam, ketamine hydrochloride, and gamma-hydroxybutyrate." Am J Health Syst Pharm.
59.11 June 1, 2002: 1067-1076.
Volkow, N.D., J.S. Fowler, G.J. Wang, et al. "Decreased dopamine D2 receptor availability is associated with reduced frontal metabolism in cocaine abusers." Synapse.
14.2 June 1993: 169-177.
Volkow, N.D., R. Hitzemann, G.J. Wang, et al. "Long-term frontal brain metabolic changes in cocaine abusers." Synapse.
11.3 July 1992: 184-190.
Weiner, A.L. "Emerging drugs of abuse in Connecticut." Conn Med.
64.1 Jan. 2000: 19-23.
Winek, C.L., W.W. Wahba, and L. Rozin. "Accidental death by nitrous oxide inhalation." Forensic Sci Int.
73.2 May 22, 1995: 139-141.
Wu, L.T., W.E. Schlenger, and D.M. Galvin. "Concurrent use of methamphetamine, MDMA, LSD, ketamine, GHB, and flunitrazepam among American youths." Drug and Alcohol Dependence
84.1 Sept. 2006: 102-113.
Zuckerman, M.D., and E.W. Boyer. "HIV and club drugs in emerging adulthood." Current Opinion in Pediatrics
24.2 Apr. 2012: 219-224.
Medically Reviewed by a Doctor on 12/22/2014
Must Read Articles Related to Club Drugs
Benzodiazepines are a type of medication known as tranquilizers. Familiar names include Valium and Xanax. They are some of the most commonly prescribed medicati...learn more >>
People abuse substances such as drugs, alcohol, and tobacco for varied and complicated reasons, but it is clear that our society pays a significant cost. Sympto...learn more >>